Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2021

01-12-2021 | Tuberculosis | Research article

Effects of undernutrition on mortality and morbidity among adults living with HIV in sub-Saharan Africa: a systematic review and meta-analysis

Authors: Animut Alebel, Daniel Demant, Pammla Petrucka, David Sibbritt

Published in: BMC Infectious Diseases | Issue 1/2021

Login to get access

Abstract

Background

Undernutrition is one of the most common problems among people living with HIV, contributing to premature death and the development of comorbidities within this population. In Sub-Saharan Africa (SSA), the impacts of these often inter-related conditions appear in a series of fragmented and inconclusive studies. Thus, this review examines the pooled effects of undernutrition on mortality and morbidities among adults living with HIV in SSA.

Methods

A systematic literature search was conducted from PubMed, EMBASE, CINAHL, and Scopus databases. All observational studies reporting the effects of undernutrition on mortality and morbidity among adults living with HIV in SSA were included. Heterogeneity between the included studies was assessed using the Cochrane Q-test and I2 statistics. Publication bias was assessed using Egger’s and Begg’s tests at a 5% significance level. Finally, a random-effects meta-analysis model was employed to estimate the overall adjusted hazard ratio.

Results

Of 4309 identified studies, 53 articles met the inclusion criteria and were included in this review. Of these, 40 studies were available for the meta-analysis. A meta-analysis of 23 cohort studies indicated that undernutrition significantly (AHR: 2.1, 95% CI: 1.8, 2.4) increased the risk of mortality among adults living with HIV, while severely undernourished adults living with HIV were at higher risk of death (AHR: 2.3, 95% CI: 1.9, 2.8) as compared to mildly undernourished adults living with HIV. Furthermore, the pooled estimates of ten cohort studies revealed that undernutrition significantly increased the risk of developing tuberculosis (AHR: 2.1, 95% CI: 1.6, 2.7) among adults living with HIV.

Conclusion

This review found that undernutrition has significant effects on mortality and morbidity among adults living with HIV. As the degree of undernutrition became more severe, mortality rate also increased. Therefore, findings from this review may be used to update the nutritional guidelines used for the management of PLHIV by different stakeholders, especially in limited-resource settings.
Appendix
Available only for authorised users
Literature
1.
2.
3.
4.
5.
6.
7.
8.
9.
Edmonds A, Yotebieng M, Lusiama J, Matumona Y, Kitetele F, Napravnik S, Cole SR, Van Rie A, Behets F. The effect of highly active antiretroviral therapy on the survival of HIV-infected children in a resource-deprived setting: a cohort study. PLoS Med. 2011;8(6):e1001044.PubMedPubMedCentralCrossRef
10.
Duggal S, Chugh TD, Duggal AK. HIV and malnutrition: effects on immune system. Clin Dev Immunol. 2012;2012.
11.
Trehan I, O'Hare BA, Phiri A, Heikens GT. Challenges in the management of HIV-infected malnourished children in sub-Saharan Africa. AIDS Res Treat. 2012;2012:790786.PubMedPubMedCentral
12.
13.
Thimmapuram R, Lanka S, Esswein A, Dall L. Correlation of nutrition with immune status in human immunodeficiency virus outpatients. Mo Med. 2019;116(4):336–9.PubMedPubMedCentral
14.
Weiser SD, Young SL, Cohen CR, Kushel MB, Tsai AC, Tien PC, Hatcher AM, Frongillo EA, Bangsberg DR. Conceptual framework for understanding the bidirectional links between food insecurity and HIV/AIDS. Am J Clin Nutr. 2011;94(6):1729s–39s.PubMedPubMedCentralCrossRef
15.
16.
França T, Ishikawa L, Zorzella-Pezavento S, Chiuso-Minicucci F, da Cunha M, Sartori A. Impact of malnutrition on immunity and infection. J Venomous Anim Toxins Incl Trop Dis. 2009;15(3):374–90.CrossRef
17.
Enwonwu CO. Complex interactions between malnutrition, infection and immunity: relevance to HIV/AIDS infection. Nig J Clin Biomed Res. 2006;1(1):6–14.
18.
Tesfamariam K, Baraki N, Kedir H. Pre-ART nutritional status and its association with mortality in adult patients enrolled on ART at fiche Hospital in North Shoa, Oromia region, Ethiopia: a retrospective cohort study. BMC Res Notes. 2016;9(1):512.PubMedPubMedCentralCrossRef
19.
Hussen S, Belachew T, Hussien N. Nutritional status and its effect on treatment outcome among HIV infected clients receiving HAART in Ethiopia: a cohort study. AIDS Res Ther. 2016;13:32.PubMedPubMedCentralCrossRef
20.
Liu E, Spiegelman D, Semu H, Hawkins C, Chalamilla G, Aveika A, Nyamsangia S, Mehta S, Mtasiwa D, Fawzi W. Nutritional status and mortality among HIV-infected patients receiving antiretroviral therapy in Tanzania. J Infect Dis. 2011;204(2):282–90.PubMedCrossRef
21.
Damtew B, Mengistie B, Alemayehu T. Survival and determinants of mortality in adult HIV/aids patients initiating antiretroviral therapy in Somali region, Eastern Ethiopia. Pan Afr Med J. 2015;22:138.PubMedPubMedCentralCrossRef
22.
Hu W, Jiang H, Chen W, He S-H, Deng B, Wang W-Y, Wang Y, Lu CD, Klassen K, Zeng J. Malnutrition in hospitalized people living with HIV/AIDS: evidence from a cross-sectional study from Chengdu, China. Asia Pac J Clin Nutr. 2011;20(4):544.PubMed
23.
Ayele T, Jarso H, Mamo G. Clinical outcomes of tenofovir versus zidovudine-based regimens among people living with hiv/aids: a two years retrospective cohort study. Open AIDS J. 2017;11:1–11.PubMedPubMedCentralCrossRef
24.
Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, Karungi G, Szumilin E, Balandine S, Fedida G, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: An effectiveness assessment. Lancet. 2006;367(9519):1335–42.PubMedCrossRef
25.
Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, Abo Y, Salamon R, Bissagnene E, Seyler C, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS. 2007;21(18):2483–91.PubMedCrossRef
26.
Moore D, Liechty C, Ekwaru P, Were W, Mwima G, Solberg P, Rutherford G, Mermin J. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS. 2007;21(6):713–9.PubMedCrossRef
27.
Toure S, Kouadio B, Seyler C, Traore M, Dakoury-Dogbo N, Duvignac J, Diakite N, Karcher S, Grundmann C, Marlink R, et al. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants. AIDS. 2008;22(7):873–82.PubMedCrossRef
28.
Hanrahan CF, Golub JE, Mohapi L, Tshabangu N, Modisenyane T, Chaisson RE, Gray GE, McIntyre JA, Martinson NA. Body mass index and risk of tuberculosis and death. AIDS. 2010;24(10):1501–8.PubMedCrossRef
29.
Evans D, Maskew M, Sanne I. Increased risk of mortality and loss to follow-up among HIVpositive patients with oropharyngeal candidiasis and malnutrition before antiretroviral therapy initiation: a retrospective analysis from a large urban cohort in Johannesburg, South Africa. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113(3):362–72.PubMedPubMedCentralCrossRef
30.
Kouanda S, Meda IB, Nikiema L, Tiendrebeogo S, Doulougou B, Kaboré I, Sanou MJ, Greenwell F, Soudré R, Sondo B. Determinants and causes of mortality in HIV-infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective cohort study. AIDS Care. 2012;24(4):478–90.PubMedCrossRef
31.
Bastard M, Nicolay N, Szumilin E, Balkan S, Poulet E, Pujades-Rodriguez M. Adults receiving HIV care before the start of antiretroviral therapy in sub-Saharan Africa: patient outcomes and associated risk factors. J Acquir Immune Defic Syndr. 2013;64(5):455–63.PubMedCrossRef
32.
Kufa T, Chihota V, Mngomezulu V, Charalambous S, Verver S, Churchyard G, Borgdorff M. The incidence of tuberculosis among hiv-positive individuals with high CD4 counts: Implications for policy. BMC Infect Dis. 2016;16(1).
33.
Ahmed A, Mekonnen D, Shiferaw AM, Belayneh F, Yenit MK. Incidence and determinants of tuberculosis infection among adult patients with HIV attending HIV care in north-east Ethiopia: A retrospective cohort study. BMJ Open. 2018;8(2).
34.
Naidoo K, Yende-Zuma N, Augustine S. A retrospective cohort study of body mass index and survival in HIV infected patients with and without TB co-infection. Infect Dis Poverty. 2018;7(1).
35.
Ssebutinde P, Kyamwanga IT, Turyakira E, Asiimwe S, Bajunirwe F. Effect of age at initiation of antiretroviral therapy on treatment outcomes; a retrospective cohort study at a large HIV clinic in southwestern Uganda. PLoS One. 2018;13(8):e0201898.PubMedPubMedCentralCrossRef
36.
Tiruneh G, Getahun A, Adeba E. Assessing the impact of isoniazid preventive therapy (IPT) on tuberculosis incidence and predictors of tuberculosis among adult patients enrolled on ART in Nekemte town Western Ethiopia: a retrospective cohort study. Interdiscip Perspect Infect Dis. 2019;2019:1413427.PubMedPubMedCentralCrossRef
37.
Nansera D, Bajunirwe F, Elyanu P, Asiimwe C, Amanyire G, Graziano FM. Mortality and loss to follow-up among tuberculosis and HIV co-infected patients in rural southwestern Uganda. Int J Tuberc Lung Dis. 2012;16(10):1371–6.PubMedCrossRef
38.
Teshome W, Moges M, Mekonnen E, Endrias M, Ayele S, Misganaw T, Shiferaw M, Tesema T. Do loss to follow-up and death rates from ART care vary across primary health care facilities and hospitals in South Ethiopia? A retrospective follow-up study. HIV/AIDS Res Palliat Care. 2015;7:167–74.CrossRef
39.
Brown JP, Ngwira B, Tafatatha T, Crampin AC, French N, Koole O. Determinants of time to antiretroviral treatment initiation and subsequent mortality on treatment in a cohort in rural northern Malawi. AIDS Res Ther. 2016;13(1).
40.
Temesgen B, Kibret GD, Alamirew NM, Melkamu MW, Hibstie YT, Petrucka P, Alebel A. Incidence and predictors of tuberculosis among HIV-positive adults on antiretroviral therapy at Debre Markos referral hospital, Northwest Ethiopia: a retrospective record review. BMC Public Health. 2019;19(1):1566.PubMedPubMedCentralCrossRef
41.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34.PubMedCrossRef
42.
43.
Ververs MT, Antierens A, Sackl A, Staderini N, Captier V. Which anthropometric indicators identify a pregnant woman as acutely malnourished and predict adverse birth outcomes in the humanitarian context? PLoS Curr. 2013;5.
44.
Purnell JQ: Definitions, Classification, and Epidemiology of Obesity. In: Endotext [Internet]. edn.: MDText. com, Inc.; 2018.
45.
Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute; 2011.
46.
Luchini C, Stubbs B, Solmi M, Veronese N. Assessing the quality of studies in meta-analyses: advantages and limitations of the Newcastle Ottawa scale. World J Metaanal. 2017;5(4):80–4.
47.
Penson D, Krishnaswami S, Jules A: Newcastle-Ottawa Quality Assessment Form for Cohort Studies. 2012. In.; 2018.
48.
Peters M, Godfrey-smith P, Mcinerney P: Guidance for the conduct of JBI scoping reviews Joanna Briggs Institute Reviewer’s Manual South Australia: Joanna Briggs Institute 2019.
49.
Kleinbaum D, Klein M, Pryor E. Logistic Regression A Self-Learning Text. Berlin: Springer; 2010.CrossRef
50.
Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J. Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. 2019;3(10).
51.
52.
Hosseinipour MC, Kumwenda JJ, Weigel R, Brown LB, Mzinganjira D, Mhango B, Eron JJ, Phiri S, van Oosterhout JJ. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med. 2010;11(8):510–8.PubMedPubMedCentral
53.
Russell EC, Charalambous S, Pemba L, Churchyard GJ, Grant AD, Fielding K. Low haemoglobin predicts early mortality among adults starting antiretroviral therapy in an HIV care programme in South Africa: a cohort study. BMC Public Health. 2010;10:433.PubMedPubMedCentralCrossRef
54.
Koethe JR, Blevins M, Nyirenda CK, Kabagambe EK, Chiasera JM, Shepherd BE, Zulu I, Heimburger DC. Serum phosphate predicts early mortality among underweight adults starting ART in Zambia: a novel context for refeeding syndrome? J Nutr Metab. 2013;2013.
55.
Molfino L, Kumar AM, Isaakidis P, Van den Bergh R, Khogali M, Hinderaker SG, Magaia A, Lobo S, Edwards CG, Walter J. High attrition among HIV-infected patients with advanced disease treated in an intermediary referral center in Maputo, Mozambique. Glob Health Action. 2014;7:23758.PubMedCrossRef
56.
Bezabhe WM, Bereznicki LR, Chalmers L, Gee P, Kassie DM, Bimirew MA, Peterson GM. Adverse dug reactions and clinical outcomes in patients initiated on antiretroviral therapy: a prospective cohort study from Ethiopia. Drug Saf. 2015;38(7):629–39.PubMedCrossRef
57.
Boullé C, Kouanfack C, Laborde-Balen G, Boyer S, Aghokeng AF, Carrieri MP, Kazé S, Dontsop M, Mben JM, Koulla-Shiro S, et al. Gender differences in adherence and response to antiretroviral treatment in the Stratall trial in rural district hospitals in Cameroon. J Acquir Immune Defic Syndr. 2015;69(3):355–64.PubMedCrossRef
58.
Bucciardini R, Fragola V, Abegaz T, Lucattini S, Halifom A, Tadesse E, Berhe M, Pugliese K, Binelli A, De Castro P, et al. Retention in care of adult HIV patients initiating antiretroviral therapy in Tigray, Ethiopia: A prospective observational cohort study. PLoS One. 2015;10(9).
59.
Herce ME, Kalanga N, Wroe EB, Keck JW, Chingoli F, Tengatenga L, Gopal S, Phiri A, Mailosi B, Bazile J, et al. Excellent clinical outcomes and retention in care for adults with HIV-associated Kaposi sarcoma treated with systemic chemotherapy and integrated antiretroviral therapy in rural Malawi. J Int AIDS Soc. 2015;18:19929.PubMedPubMedCentralCrossRef
60.
Stete K, Glass TR, van Dam GJ, Ntamatungiro A, Letang E, de Dood CJ, Corstjens PLAM, Ndege R, Mapesi H, Kern WV, et al. Effect of schistosomiasis on the outcome of patients infected with HIV-1 starting antiretroviral therapy in rural Tanzania. PLoS Negl Trop Dis. 2018;12(10).
61.
Van Der Sande MAB, Van Der Loeff MF, Aveika AA, Sabally S, Togun T, Sarge-Njie R, Alabi AS, Jaye A, Corrah T, Whittle HC. Body mass index at time of HIV diagnosis: a strong and independent predictor of survival. J Acquir Immune Defic Syndr. 2004;37(2):1288–94.PubMedCrossRef
62.
Nakanjako D, Mayanja-Kizza H, Ouma J, Wanyenze R, Mwesigire D, Namale A, Ssempiira J, Senkusu J, Colebunders R, Kamya MR. Tuberculosis and human immunodeficiency virus co-infections and their predictors at a hospital-based HIV/AIDS clinic in Uganda. Intl J Tuberc Lung Dis. 2010;14(12):1621–8.
63.
Van Rie A, Westreich D, Sanne I. Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr. 2011;56(4):349–55.PubMedPubMedCentralCrossRef
64.
Hoffmann CJ, Chaisson RE, Martinson NA. Cotrimoxazole prophylaxis and tuberculosis risk among people living with HIV. PLoS One. 2014;9(1).
65.
Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a south African cohort. Aids. 2005;19(18):2109–16.PubMedCrossRef
66.
Holmes CB, Wood R, Badri M, Zilber S, Wang B, Maartens G, Zheng H, Lu Z, Freedberg KA, Losina E. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr. 2006;42(4):464–9.PubMedCrossRef
67.
Kasonka L, Makasa M, Marshall T, Chisenga M, Sinkala M, Chintu C, Kaseba C, Kasolo F, Gitau R, Tomkins A et al: Risk factors for subclinical mastitis among HIV-infected and uninfected women in Lusaka, Zambia. Paediatr Perinat Epidemiol 2006, 20(5):379–391.
68.
Donovan C, Massingue J. Illness, death, and macronutrients: adequacy of rural Mozambican household production of macronutrients in the face of HIV/AIDS. Food Nutr Bull. 2007;28(2 Suppl):S331–8.PubMedCrossRef
69.
Estopinal CB, van Dijk JH, Sitali S, Stewart H, Davidson MA, Spurrier J, Vermund SH. Availability of volunteer-led home-based care system and baseline factors as predictors of clinical outcomes in HIV-infected patients in rural Zambia. PLoS One. 2012;7(12):e49564.PubMedPubMedCentralCrossRef
70.
Henostroza G, Harris JB, Chitambi R, Siyambango M, Turnbull ER, Maggard KR, Krüüner A, Kapata N, Reid SE. High prevalence of tuberculosis in newly enrolled HIV patients in Zambia: need for enhanced screening approach. Int J Tuberc Lung Dis. 2016;20(8):1033–9.PubMedCrossRef
71.
Sørensen A, Jespersen S, Katzenstein TL, Medina C, da Silva TD, Correira FG, Hviid CJ, Laursen AL, Wejse C. Clinical presentation and opportunistic infections in HIV-1, HIV-2 and HIV-1/2 dual seropositive patients in Guinea-Bissau. Infect Dis. 2016;48(8):604–11.CrossRef
72.
Bebell LM, Siedner MJ, Musinguzi N, Boum Y, Bwana BM, Muyindike W, Hunt PW, Martin JN, Bangsberg DR. Trends in one-year cumulative incidence of death between 2005 and 2013 among patients initiating antiretroviral therapy in Uganda. Int J STD AIDS. 2017;28(8):800–7.PubMedCrossRef
73.
Giri PA, Deshpande JD, Phalke DB. Prevalence of pulmonary tuberculosis among HIV positive patients attending antiretroviral therapy clinic. North Am J Med Sci. 2013;5(6):367–70.CrossRef
74.
McCarthy KM, Morgan J, Wannemuehler KA, Mirza SA, Gould SM, Mhlongo N, Moeng P, Maloba BR, Crewe-Brown HH, Brandt ME, et al. Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence. AIDS. 2006;20(17):2199–206.PubMedCrossRef
75.
Oyella J, Meya D, Bajunirwe F, Kamya MR. Prevalence and factors associated with cryptococcal antigenemia among severely immunosuppressed HIV-infected adults in Uganda: a cross-sectional study. J Int AIDS Soc. 2012;15(1).
76.
Tadege M. Time to death predictors of HIV/AIDS infected patients on antiretroviral therapy in Ethiopia. BMC Res Notes. 2018;11(1).
77.
Asiimwe SB, Laker-Oketta M, Bennett J, Mocello A, Glidden D, Haberer J, Bwana M, Hunt P, Bangsberg D, Mbidde E et al: Impact of Kaposi sarcoma on survival in HIV-infected African adults on antiretroviral therapy. In: Topics in Antiviral Medicine vol. 22; 2014: 51.
78.
Herce ME, Kalanga N, Crocker JT, Wroe EB, Keck JW, Chingoli FD, Gopal S, Bazile J, Beste JA, Rigodon J: HIV-associated Kaposi sarcoma treated with chemotherapy and ART in rural Malawi. Topics in Antiviral Medicine 2015, 23((Chingoli F.D.) Ministry of Health of the Republic of Malawi, Neno, Malawi):319–320.
79.
Kilama BK, Moshiro C, Todd J, Ramadhani A, Mmbando D: Patient level findings: Pre-ART mortality and its determinants in Tanzania public-driven HIV care program (2004–2011). Topics in Antiviral Medicine 2015, 23((Todd J.) London School of Hygiene and Tropical Medicine, London, United Kingdom):497–498.
80.
Umanah T, Ncayiyana J, Padanilam X, Nyasulu PS: Outcomes of multidrug resistant tuberculosis treatment among human immunodeficiency virus co-infected patients taking anti-retroviral treatment at Sizwe Tropical Disease Hospital Johannesburg, South Africa. International Journal of Infectious Diseases 2016, 45((Nyasulu P.S.) Monash University, Johannesburg, Gauteng, South Africa):403.
81.
Adebamowo SN, Adebamowo CA, Odutola M, Famooto A, Adebayo A, Alabi B, Obende K, Offiong R, Ologun S, Achara P, et al. Incidence, persistence, and determinants of human papillomavirus: a prospective cohort study of HIV-negative Nigerian women. J Glob Oncol. 2017;3(2):39S–40S.CrossRef
82.
Hector J, Vinikoor MJ, Musukuma K, Chilengi R, Jefferys L, Hobbins MA, Davies MA, Egger M, Wandeler G. Mortality of HIV/HBV coinfected patients on art in urban and rural Southern Africa. Topics Antivir Med. 2017;25(1):241s.
83.
Argemi X, Dara S, You S, Mattei JF, Courpotin C, Simon B, Hansmann Y, Christmann D, Lefebvre N. Impact of malnutrition and social determinants on survival of HIV-infected adults starting antiretroviral therapy in resource-limited settings. AIDS. 2012;26(9):1161–6.PubMedCrossRef
84.
Benova L, Fielding K, Greig J, Nyang'wa BT, Casas EC, da Fonseca MS, du Cros P. Association of BMI category change with TB treatment mortality in HIV-positive smear-negative and extrapulmonary TB patients in Myanmar and Zimbabwe. PLoS One. 2012;7(4).
85.
Choun K, Thai S, Pe R, Lorent N, Lynen L, van Griensven J. Incidence and risk factors for tuberculosis in HIV-infected patients while on antiretroviral treatment in Cambodia. Trans R Soc Trop Med Hyg. 2013;107(4):235–42.PubMedCrossRef
86.
Sharma A, Hoover DR, Shi Q, Gustafson D, Plankey MW, Hershow RC, Tien PC, Golub ET, Anastos K. Relationship between body mass index and mortality in HIV-infected HAART users in the women's interagency HIV study. PLoS One. 2015;10(12).
87.
Kumar N, Aithal S, Unnikrishnan B, Ramapuram J, Thapar R, Mithra P, Kulkarni V, Holla R. Predictors of mortality among a cohort of HIV/AIDS patients on anti-retroviral therapy in coastal South India. HIV AIDS Rev. 2017;16(1):18–23.CrossRef
88.
Jiang J, Qin X, Liu H, Meng S, Abdullah AS, Huang J, Qin C, Liu Y, Huang Y, Qin F, et al. An optimal BMI range associated with a lower risk of mortality among HIV-infected adults initiating antiretroviral therapy in Guangxi, China. Sci Rep. 2019;9(1).
89.
Frigati LJ, Kranzer K, Cotton MF, Schaaf HS, Lombard CJ, Zar HJ. The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting. Thorax. 2011;66(6):496–501.PubMedCrossRef
90.
Ebissa G, Deyessa N, Biadgilign S. Predictors of early mortality in a cohort of HIV-infected children receiving high active antiretroviral treatment in public hospitals in Ethiopia. AIDS Care. 2015;27(6):723–30.PubMedCrossRef
91.
Liotta G, Mancinelli S, Nielsen-Saines K, Gennaro E, Gennaro E, Scarcella P, Magid NA, Germano P, Jere H, Guidotti G, et al. Reduction of maternal mortality with highly active antiretroviral therapy in a large cohort of HIV-infected pregnant women in Malawi and Mozambique. PLoS One. 2013;8(8):e71653.PubMedPubMedCentralCrossRef
92.
Li N, Matchi E, Spiegelman D, Chalamilla G, Hertzmank E, Sando D, Sando MM, Liu E, Muya A, Fawzi W. Maternal mortality among HIV-infected pregnant women in Tanzania. Acta Obstet Gynecol Scand. 2014;93(5):463–8.PubMedCrossRef
93.
Woodd SL, Kelly P, Koethe JR, Praygod G, Rehman AM, Chisenga M, Siame J, Heimburger DC, Friis H, Filteau S. Risk factors for mortality among malnourished HIV-infected adults eligible for antiretroviral therapy. BMC Infect Dis. 2016;16(1).
94.
Chandrasekhar A, Gupta A. Nutrition and disease progression pre-highly active antiretroviral therapy (HAART) and post-HAART: can good nutrition delay time to HAART and affect response to HAART? Am J Clin Nutr. 2011;94(6):1703S–15S.PubMedPubMedCentralCrossRef
95.
Kendi C, Penner J, Koech J, Nyonda M, Cohen CR, Bukusi EA, Ngugi E, Meyer ACL. Predictors of outcome in routine care for Cryptococcal meningitis in Western Kenya: lessons for HIV outpatient care in resource-limited settings. Postgrad Med J. 2013;89(1048):73–7.PubMedCrossRef
96.
Sabasaba A, Mwambi H, Somi G, Ramadhani A, Mahande MJ. Effect of isoniazid preventive therapy on tuberculosis incidence and associated risk factors among HIV infected adults in Tanzania: a retrospective cohort study. BMC Infect Dis. 2019;19(1).
97.
Kyeyune R, Saathoff E, Ezeamama AE, Löscher T, Fawzi W, Guwatudde D. Prevalence and correlates of cytopenias in HIV-infected adults initiating highly active antiretroviral therapy in Uganda. BMC Infect Dis. 2014;14(1).
98.
Palombi L, Marazzi MC, Guidotti G, Germano P, Buonomo E, Scarcella P, Doro Altan A, Zimba Ida V, San Lio MM, De Luca A. Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African sites with comprehensive monitoring availability. Clin Infect Dis. 2009;48(1):115–22.PubMedCrossRef
99.
Jerene D, Endale A, Hailu Y, Lindtjøorn B. Predictors of early death in a cohort of Ethiopian patients treated with HAART. BMC Infect Dis. 2006;6.
100.
Johannessen A, Naman E, Ngowi BJ, Sandvik L, Matee MI, Aglen HE, Gundersen SG, Bruun JN. Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis. 2008;8:52.PubMedPubMedCentralCrossRef
101.
Dao CN, Peters PJ, Kiarie JN, Zulu I, Muiruri P, Ong'Ech J, Mutsotso W, Potter D, Njobvu L, Stringer JSA, et al. Hyponatremia, hypochloremia, and hypoalbuminemia predict an increased risk of mortality during the first year of antiretroviral therapy among HIV-infected Zambian and Kenyan women. AIDS Res Hum Retrovir. 2011;27(11):1149–55.PubMedCrossRef
102.
Masiira B, Baisley K, Mayanja BN, Kazooba P, Maher D, Kaleebu P. Mortality and its predictors among antiretroviral therapy naïve HIV-infected individuals with CD4 cell count ≥350 cells/mm(3) compared to the general population: data from a population-based prospective HIV cohort in Uganda. Glob Health Action. 2014;7:21843.PubMedCrossRef
103.
Chen SC, Yu JK, Harries AD, Bong CN, Kolola-Dzimadzi R, Tok TS, King CC, Wang JD. Increased mortality of male adults with AIDS related to poor compliance to antiretroviral therapy in Malawi. Trop Med Int Health. 2008;13(4):513–9.PubMedCrossRef
104.
Sieleunou I, Souleymanou M, Schönenberger AM, Menten J, Boelaert M. Determinants of survival in AIDS patients on antiretroviral therapy in a rural Centre in the far-North Province, Cameroon. Trop Med Int. 2009;14(1):36–43.CrossRef
105.
Geng EH, Bwana MB, Muyindike W, Glidden DV, Bangsberg DR, Neilands TB, Bernheimer I, Musinguzi N, Yiannoutsos CT, Martin JN. Failure to initiate antiretroviral therapy, loss to follow-up and mortality among HIV-infected patients during the pre-ART period in Uganda. J Acquir Immune Defic Syndr. 2013;63(2):e64–71.PubMedPubMedCentralCrossRef
106.
Hoffmann CJ, Fielding KL, Johnston V, Charalambous S, Innes C, Moore RD, Chaisson RE, Grant AD, Churchyard GJ. Changing predictors of mortality over time from cART start: implications for care. J Acquir Immune Defic Syndr. 2011;58(3):269–73.PubMedPubMedCentralCrossRef
107.
Maman D, Pujades-Rodriguez M, Nicholas S, McGuire M, Szumilin E, Ecochard R, Etard JF. Response to antiretroviral therapy: improved survival associated with CD4 above 500 cells/μl. AIDS. 2012;26(11):1393–8.PubMedCrossRef
108.
Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, Mtonga V, Reid S, Cantrell RA, Bulterys M, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006;296(7):782–93.PubMedCrossRef
109.
Pac L, Horwitz MM, Namutebi AM, Auerbach BJ, Semeere A, Namulema T, Schwarz M, Bbosa R, Muruta A, Meya DB, et al. Implementation and operational research: integrated pre-antiretroviral therapy screening and treatment for tuberculosis and cryptococcal antigenemia. J Acquir Immune Defic Syndr. 2015;68(5):e69–76.PubMedPubMedCentralCrossRef
110.
Tchounga BK, Hønge BL, Eholie SP, Coffie PA, Jespersen S, Wejse C, Dabis F, Geoffrey GS, Ekouevi DK. Effect of sex and age on outcomes among HIV-2-infected patients starting antiretroviral therapy in West Africa. AIDS. 2016;30(17):2707–14.PubMedCrossRef
111.
Otwombe KN, Petzold M, Modisenyane T, Martinson NA, Chirwa T. Factors associated with mortality in HIV-infected people in rural and urban South Africa. Glob Health Action. 2014;7(1).
112.
Zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Arnould L, Makombe S, Harries AD. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS. 2006;20(18):2355–60.PubMedCrossRef
113.
Worodria W, Massinga-Loembe M, Mayanja-Kizza H, Namaganda J, Kambugu A, Manabe YC, Kestens L, Colebunders R. Antiretroviral treatment-associated tuberculosis in a prospective cohort of HIV-infected patients starting ART. Clin Dev Immunol. 2011;2011:758350.PubMedCrossRef
114.
Nicholas S, Sabapathy K, Ferreyra C, Varaine F, Pujades-Rodríguez M. Incidence of tuberculosis in HIV-infected patients before and after starting combined antiretroviral therapy in 8 sub-Saharan African HIV programs. J Acquir Immune Defic Syndr. 2011;57(4):311–8.PubMedCrossRef
115.
Liu E, Makubi A, Drain P, Spiegelman D, Sando D, Li N, Chalamilla G, Sudfeld CR, Hertzmark E, Fawzi WW. Tuberculosis incidence rate and risk factors among HIV-infected adults with access to antiretroviral therapy. AIDS. 2015;29(11):1391–9.PubMedCrossRef
116.
Chang CA, Meloni ST, Eisen G, Chaplin B, Akande P, Okonkwo P, Rawizza HE, Tchetgen ET, Kanki PJ. Tuberculosis incidence and risk factors among human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy in a large HIV program in Nigeria. Open Forum Infect Dis. 2015;2(4):1–11.CrossRef
117.
Bjerrum S, Oliver-Commey J, Kenu E, Lartey M, Newman MJ, Addo KK, Hilleman D, Andersen AB, Johansen IS. Tuberculosis and non-tuberculous mycobacteria among HIV-infected individuals in Ghana. Trop Med Int Health. 2016;21(9):1181–90.PubMedCrossRef
118.
Mupfumi L, Moyo S, Molebatsi K, Thami PK, Anderson M, Mogashoa T, Iketleng T, Makhema J, Marlink R, Kasvosve I, et al. Immunological non-response and low hemoglobin levels are predictors of incident tuberculosis among HIV-infected individuals on Truvada-based therapy in Botswana. PLoS One. 2018;13(1).
119.
Melkamu H, Seyoum B, Dessie Y. Determinants of tuberculosis infection among adult HIV-positives attending clinical care in Western Ethiopia: a case-control study. AIDS Res Treat. 2013;2013:279876.PubMedPubMedCentral
120.
Gedle D, Kumera G, Eshete T, Ketema K, Adugna H, Feyera F. Intestinal parasitic infections and its association with undernutrition and CD4 T cell levels among HIV/AIDS patients on HAART in Butajira, Ethiopia. J Health Popul Nutr. 2017;36(1):15.PubMedPubMedCentralCrossRef
121.
Ageru TA, Koyra MM, Gidebo KD, Abiso TL. Anemia and its associated factors among adult people living with human immunodeficiency virus at Wolaita Sodo University teaching referral hospital. PLoS One. 2019;14(10):e0221853.PubMedPubMedCentralCrossRef
122.
Chen YN, Wall KM, Fofana K, Navarro-Colorado C. Nutrition indicators as potential predictors of AIDS-defining illnesses among ARV-naïve HIVpositive adults in Kapiri Mposhi, Zambia 2008-2009. PLoS One. 2019;14(7).
123.
Hussen S, Belachew T, Hussein N. Nutritional status of HIV clients receiving HAART: Its omplication on occurrence of opportunistic infection. The Open Public Health J. 2017;10(1).
124.
Umanah T, Ncayiyana J, Padanilam X, Nyasulu PS. Treatment outcomes in multidrug resistant tuberculosis-human immunodeficiency virus co-infected patients on anti-retroviral therapy at Sizwe tropical disease hospital Johannesburg, South Africa. BMC Infect Dis. 2015;15:478.PubMedPubMedCentralCrossRef
125.
Hughes S, Kelly P. Interactions of malnutrition and immune impairment, with specific reference to immunity against parasites. Parasite Immunol. 2006;28(11):577–88.PubMedPubMedCentral
126.
Candiani TM, Pinto J, Cardoso CA, Carvalho IR, Dias AC, Carneiro M, Goulart EA. Impact of highly active antiretroviral therapy (HAART) on the incidence of opportunistic infections, hospitalizations and mortality among children and adolescents living with HIV/AIDS in Belo Horizonte, Minas Gerais state, Brazil. Cad Saude Publica. 2007;23(Suppl 3):S414–23.PubMedCrossRef
127.
Mermin J, Were W, Ekwaru JP, Moore D, Downing R, Behumbiize P, Lule JR, Coutinho A, Tappero J, Bunnell R. Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet. 2008;371(9614):752–9.PubMedCrossRef
128.
Berhe N, Tegabu D, Alemayehu M. Effect of nutritional factors on adherence to antiretroviral therapy among HIV-infected adults: a case control study in northern Ethiopia. BMC Infect Dis. 2013;13:233.PubMedPubMedCentralCrossRef
129.
Young S, Wheeler AC, McCoy SI, Weiser SD. A review of the role of food insecurity in adherence to care and treatment among adult and pediatric populations living with HIV and AIDS. AIDS Behav. 2014;18(Suppl 5):S505–15.PubMedCrossRef
130.
Iacob SA, Iacob DG, Jugulete G. Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful hiv treatment—clinical points of view and practical considerations. Front Pharmacol. 2017;8:831.PubMedPubMedCentralCrossRef
131.
Rai S, Mahapatra B, Sircar S, Raj PY, Venkatesh S, Shaukat M, Rewari BB. Adherence to antiretroviral therapy and its effect on survival of HIV-infected individuals in Jharkhand, India. PLoS One. 2013;8(6):e66860.PubMedPubMedCentralCrossRef
132.
Biset Ayalew M. Mortality and its predictors among HIV infected patients taking antiretroviral treatment in Ethiopia: a systematic review. AIDS Res Treat. 2017;2017.
133.
Ahmed M, Merga H, Jarso H. Predictors of virological treatment failure among adult HIV patients on first-line antiretroviral therapy in Woldia and Dessie hospitals, Northeast Ethiopia: a case-control study. BMC Infect Dis. 2019;19(1):305.PubMedPubMedCentralCrossRef
134.
Pujades-Rodriguez M, Balkan S, Arnould L, Brinkhof MA, Calmy A. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. J Am Med Assoc. 2010;304(3):303–12.CrossRef
135.
Pettersen PS, Brox IK, Naman E, Bruun JN, Dyrhol-Riise AM, Troseid M, Johannessen A. Antiretroviral treatment failure predicts mortality in rural Tanzania. Int J STDs AIDS. 2015;26(9):633–9.CrossRef
136.
Scrimshaw NS. Historical concepts of interactions, synergism and antagonism between nutrition and infection. J Nutr. 2003;133(1):316S–21S.PubMedCrossRef
137.
138.
Lonnroth K, Williams BG, Cegielski P, Dye C. A consistent log-linear relationship between tuberculosis incidence and body mass index. Int J Epidemiol. 2010;39(1):149–55.PubMedCrossRef
139.
140.
Padmapriyadarsini C, Shobana M, Lakshmi M, Beena T, Swaminathan S. Undernutrition & tuberculosis in India: situation analysis & the way forward. Indian J Med Res. 2016;144(1):11–20.PubMedPubMedCentralCrossRef
141.
142.
Gupta KB, Gupta R, Atreja A, Verma M, Vishvkarma S. Tuberculosis and nutrition. Lung India Official Organ Indian Chest Soc. 2009;26(1):9.CrossRef
143.
FAO I, & WFP, : & WFP (world food Programme). In: Achieving Zero Hunger The critical role of investment in social protection and agriculture Rome, FAO. Edited by Nations FaAOotU; 2015.
144.
World Health Organization. Guideline: nutritional care and support for patients with tuberculosis. Geneva: World Health Organization; 2013.
145.
146.
Zanoni BC, Gandhi RT. Update on opportunistic infections in the era of effective antiretroviral therapy. Infect Dis Clinic North Am. 2014;28(3):501–18.CrossRef
147.
The Ethiopian Federal Ministry of Health: National Comprehensive HIV Prevention, Care and Treatment Training for Health care Providers. In.; 2017.
148.
Filteau S, PrayGod G, Kasonka L, Woodd S, Rehman AM, Chisenga M, Siame J, Koethe JR, Changalucha J, Michael D, et al. Effects on mortality of a nutritional intervention for malnourished HIV-infected adults referred for antiretroviral therapy: a randomised controlled trial. BMC Med. 2015;13:17.PubMedPubMedCentralCrossRef
149.
Mallewa J, Szubert AJ, Mugyenyi P, Chidziva E, Thomason MJ, Chepkorir P, Abongomera G, Baleeta K, Etyang A, Warambwa C, et al. Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial. Lancet HIV. 2018;5(5):e231–40.PubMedPubMedCentralCrossRef
150.
PrayGod G, Friis H, Filteau S. Nutritional support to reduce mortality in patients with HIV? Lancet HIV. 2018;5(5):e202–4.PubMedCrossRef
151.
152.
Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22(15):1897–908.PubMedCrossRef
Metadata
Title
Effects of undernutrition on mortality and morbidity among adults living with HIV in sub-Saharan Africa: a systematic review and meta-analysis
Authors
Animut Alebel
Daniel Demant
Pammla Petrucka
David Sibbritt
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2021
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-020-05706-z

Other articles of this Issue 1/2021

BMC Infectious Diseases 1/2021 Go to the issue

Research article

A two-component intervention to improve hand hygiene practices and promote alcohol-based hand rub use among people who inject drugs: a mixed-methods evaluation

Correction

Correction to: The health-related quality of life in Iranian patients with COVID-19

Research article

Evaluating an app-guided self-test for influenza: lessons learned for improving the feasibility of study designs to evaluate self-tests for respiratory viruses

Research

Associations between YKL-40 and markers of disease severity and death in patients with necrotizing soft-tissue infection

Correction

Correction to: Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study

Research article

Polymorphism rs368234815 of interferon lambda 4 gene and spontaneous clearance of hepatitis C virus in haemodialysis patients: a case-control study

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits